PhenomeX AAQS 2024

PhenomeX는 무엇을 하나요?

The company Berkeley Lights Inc. (BLI) is a biotech startup that was founded in 2011 by Eric Hobbs and Igor Khandros in California. They both had experience in the semiconductor electronics field and decided to utilize their skills to develop a new technology that allows researchers to quickly and efficiently investigate cell-specific processes. The concept behind BLI is based on a novel technology called the "Beacon system." Cells are held on thousands of tiny microchips and can be selectively manipulated using beams of light. The Beacon system enables researchers to isolate, analyze, and select cells rapidly and efficiently, significantly speeding up and simplifying the research process. BLI's business model can be described as B2B, as the company sells its technology and services to other companies in the biotech industry. BLI has two different divisions in which it utilizes its technology and expertise: the "OptoSelect" program and the "Beacon Discovery" program. BLI's OptoSelect program offers customers the ability to select precise and specific cell lines from a large array of cultures. BLI utilizes its Beacon technology to quickly and efficiently isolate and select cells, saving valuable time and resources for researchers. These cell lines can then be used in the development of drugs and therapies, increasing the chances of successful market introduction. BLI's Beacon Discovery program is focused on accelerating the discovery process of new drugs and therapies. BLI works closely with its customers to expedite the drug development process. By using the Beacon technology, it is possible to identify and test potential drug candidates more quickly, significantly reducing the development time. BLI also offers a range of products based on the Beacon technology. These include devices such as the Lightning™ Digital Array, a system for multi-omics analysis of gene expression, immune response, and cell cycle; the Beacon® Controller, a system for controlling the Beacon® microchip platform; and the Beacon® Pak for consumables. Since its founding, BLI has conducted multiple funding rounds and raised over $180 million for the development of its technology and services. The company has established strong partnerships with leading companies in the biotech industry and collaborates closely with researchers and universities to advance its technology. Overall, BLI has established itself as a leading provider of biotech technologies. Through the use of its Beacon technology, the company has accelerated and simplified the process of cell analysis and selection, speeding up the development of new drugs and therapies and increasing the chances of successful market introduction. With its state-of-the-art products and services, BLI is well-positioned to continue playing a significant role in the biotech industry in the future. PhenomeX ist eines der beliebtesten Unternehmen auf Eulerpool.com.